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Molecular structure and function of angiotensin type 2 receptor. More
than two isoforms have been identified for angiotensin receptors based on
their ligand selectivity. The objective of this study is to determine the
molecular structure of angiotensin type 2 receptor (AT2), whose physio-
logical functions are still an enigma despite extensive studies on its
distribution in fetal tissues. We expression-cloned a eDNA of an affinity-
purified AT2 from rat pheochromocytoma cells (PC12w). The AT2 eDNA
clone comprises 2,868 nucleotides and encodes a 363 amino acid protein
with seven putative transmembrane domains. The dissociation constant
for its binding to '251-C0P42112A, an AT2-specific ligand, was 0.11 0.01
nM. Its binding to 0.5 nM 'I-[Sar1, Ile8I-Ang II was not inhibited by Dup
753 but by PD123319 (IC50 = 1.7 0.2 nM). These binding features are
characteristic of angiotensin type 2 receptor. The amino acid sequence
analysis of the purified AT2 corroborated the amino terminus of the
deduced primary structure of AT2. Angiotensin type 1 receptor (AT1) is
the most closely related to AT2 but with only 32% amino acid sequence
identity. Angiotensin II attenuated membrane-associated protein tyrosine
phosphatase activity in the COS-7 cells stably expressing AT2 through a
pertussis toxin-sensitive G protein. However, the physiological function of
AT2 in the fetal kidney is still unresolved.
There are at least two isoforms identified for angiotensin (Ang)
receptors with respect to their ligand selectivity [11. Ang type 1
receptor (AT1) is a U-protein coupled glycoprotein which medi-
ates well-known biological functions exerted by angiotensin II
(Ang II) [2, 3], whereas the type 2 receptor (AT2) is not
well-characterized biologically or structurally. However AT2 is
widely distributed in fetal tissues including the kidney and has
been postulated to be involved in fetal development and organo-
genesis [4]. In the present study we isolated an AT2 eDNA clone
from rat pheochromocytoma cells (PC12w) and determined its
nucleotide sequence. Here we report that AT2 is a discrete
member of the seven-transmembrane-domain receptor family and
its possible involvement in protein tyrosine phosphatase (PTPase)
activity is discussed.
Methods
A cDNA library was constructed from rat PC12w cells using a
mammalian expression vector, pCDNAI (Invitrogen). COS-7 cells
were transfected with plasmid DNA prepared for pools of around
300 individual clones and screened by binding to 1251-[Sart,
Ile8]-Ang II or CGP42112A, an AT2-specific ligand. Subsequently
matrix screening was repeated twice and a eDNA clone of 2.9 kb
was isolated. The dideoxynucleotide chain termination method
was used for nucleotide sequencing. Stably transfected COS-7
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cells were established with pRc/CMV (Invitrogen) harbouring the
AT2 eDNA and were used for binding and functional analyses.
Soluble extract was prepared from plasma membranes of
PC12w cells using CHAPS and digitonin according to Regan [5]
and incubated with biotinylated Ang II (1 nM), which was derived
from Ang II and sulfosuccinimidyl 2-(biotinamido)ethyl-1,3-
dithio-propionate (Pierce), and purified by affinity chromatogra-
phy on avidin-agarose. The final purification was carried out by
SDS-polyacrylamide gel (7.5%) electrophoresis. The separated
proteins were blotted to a PVDF-treated nylon membrane and
used for structural analysis of AT2.
Binding and functional studies were performed as described
previously [6]. PTPase activity was measured as a release of
[32P]-phosphoric acid from 32P-labeled Raytide (Oncogene Sci-
ence). Incubation with agonist was carried out for 20 minutes at
23°C before the PTPase assay.
Results
The AT2 eDNA clone comprises 2,868 nucleotides and encodes
a 363 amino acid protein in an open reading frame. As shown in
Figure 1, AT2 has seven putative transmembrane domains as does
AT1, but the amino acid sequence identity between them is only
32%, which is in great contrast with the 94% sequence identity
between AT1 subtypes, ATIA and AT1. Thus AT2 is a novel
member of the seven-transmembrane-domain receptor family.
At the same time we attempted to isolate AT2 and determine its
N-terminal sequence. From 1.7 g of plasma membranes of PC12w
cells, 0.587 g of protein was extracted in a buffer containing
CHAPS and digitonin (solubilization yield: 33%). The dissocia-
tion constant for the binding to 1251-CGP42112A was increased
from 0.743 flM to 4.985 nM. In the affinity chromatography we
could purify AT2 into near homogeneity, but its binding activity
was already lost probably because the structural integrity of AT2
required for its biological activity was deteriorated by removing
any components of plasma membranes. Nevertheless, we could
determine its N-terminal sequence directly from the nylon mem-
brane to which AT2 was transblotted. It agreed with the N-
terminal sequence deduced from the eDNA.
Scatchard analysis revealed that the dissociation constant for
the binding of the cloned AT2 to '251-CGP421 12A was 0.11 0.01
nM (N = 3). Table I shows the inhibitory constants of various Ang
Il-related compounds for the binding of the cloned AT2 to
1251-[Sar1, 11e8}-Ang II. Dup 753, an AT1-specific ligand, did not
affect its binding to 1251-[Sar1, 11e8]-Ang II even at 1 M, whereas
PD123319, an AT2-specific nonpeptide ligand, inhibited it with an
IC50 of 1.7 flM.
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Angiotensin II did not alter the concentration of cAMP or
cGMP in PC12w cells and the COS-7 cells stably transfected with
the AT2 cDNA whether or not they were stimulated by ANF. As
it was hypothesized that AT2 might mediate Ang 11-induced
modulation of PTPase activity [7], we assessed the effects of Ang
II on the COS-7 cells stably expressing AT2. However, this
receptor showed inhibition of PTPase. This Ang 11-induced
PTPase inhibition was dose-dependent and pertussis toxin-sensi-
tive.
Discussion
The physiological functions of AT2 are still elusive despite
several reports on its functions. One of the foremost reasons for
this elusiveness is the lack of information on the molecular
structure and signalling mechanism of AT2. The present study has
clearly demonstrated that AT2 is a novel senven-transmembrane-
domain receptor with only 32% amino acid sequence identity with
AT1 isoforms from the results on the sequence analyses of the
isolated protein as well as cDNA of AT2. Thus AT2 may exert its
functions through G-proteins.
It should be noted that the binding activity of AT2 is not
affected by non-hydrolyzable GTP-analogues. A similar feature is
known for certain subtypes of dopamine and somatostatin recep-
tors [8, 9]. Thus, AT2 and these receptors form a special class of
seven-transmembrane-domain receptor family whose coupling
with G-proteins is not tight or does not affect their binding to a
ligand.
The functional studies using an AT2 cDNA clone revealed that
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Fig. 1. Alignment of deduced amino acid sequences of rat angiotensin receptors. Amino acids are denoted by single-letter code. Identical and homologous
amino acid residues are indicated by solid and dotted lines, respectively. Putative transmembrane domains are underlined.
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(359)
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Compound IC50 nM
Angiotensin I 341 20
Angiotensin II 1.4 0.1
Angiotensin III 0.98 0.05
Dup 753 > 1000
PD123319 1.7 0.2
Vasopressin > 1000
Endothelin > 1000
IC50 values were determined as the concentrations required to inhibit
50% of the binding of the COS-7 cells stably expressing AT2 to 0.5 nr'i
1I-[Sar1, 11e8}-angiotensin II. Data are expressed as mean SEM of three
separate experiments.
AT2 appears not to be involved in cAMP, cGMP productions or
calcium mobilization but reduces PTPase activity. PTPase can
counteract with tyrosine kinases and is thought to play a critical
role in cell growth, differentiation and metabolism. The identity of
the particular PTPase inhibited by AT2 is not clear. Thus, its
physiological role is not yet known. But it is interesting to relate
the unique function of AT2 to its abundant expression in fetal
tissues of late gestation [2].
Studies using AT2-specific antagonists suggest the renal func-
tion of Ang II through AT2 [10, 11]. Furthermore, it is also known
that AT2 abundantly exists in fetal and neonatal kidneys [12].
Thus the cloned AT2 might play a functional role in the kidney as
well.
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